| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 01/29/2002 | US6342510 Antiinflammatory agents and enzyme inhibitors |
| 01/29/2002 | US6342505 Use of 4-substituted tetrahydropyridines for making medicines acting on TGF-β1 |
| 01/29/2002 | US6342496 Bupropion metabolites and methods of use |
| 01/29/2002 | CA2145296C Benzenealkanoic acids for cardiovascular diseases |
| 01/27/2002 | CA2353768A1 Use of growth hormone secretagogues for improvement of functional health status |
| 01/24/2002 | WO2002006529A2 Detection and treatment of polycystic kidney disease |
| 01/24/2002 | WO2002006492A1 A novel human soluble secreted endopeptidase (sep) for the treatment of sexual dysunfction |
| 01/24/2002 | WO2002006288A1 Tetrahydro-heterocycloazepinyl pyrimidine derivatives |
| 01/24/2002 | WO2002006284A1 Indoloquinazolinones |
| 01/24/2002 | WO2002006274A1 N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists |
| 01/24/2002 | WO2002006272A1 Polyfluoroalkyltriazole derivatives, preparation and therapeutic use thereof |
| 01/24/2002 | WO2002006271A1 Pyrimidine derivatives |
| 01/24/2002 | WO2002006254A1 Tetrazole derivatives |
| 01/24/2002 | WO2002006253A1 Valsartan salts |
| 01/24/2002 | WO2002006241A1 1, 2, 3, 5 -tetrahydrobenzo`c!azepin-4-one derivatives having muscarinic antagonist activity |
| 01/24/2002 | WO2002006236A1 N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
| 01/24/2002 | WO2002006232A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| 01/24/2002 | WO2002006224A1 Pyrrolidine-2-carboxylic acid hydrazide derivatives for use as metalloprotease inhibitors |
| 01/24/2002 | WO2002006222A1 Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme |
| 01/24/2002 | WO2002005828A1 Compositions and methods for the treatment of skin damage |
| 01/24/2002 | WO2002005795A2 Pharmaceutical combinations for treatment and prevention of diabetes mellitus |
| 01/24/2002 | WO2002005794A2 Use of fluorescein derivatives for the treatment of diseases responsive to the activation of the cystic fibrosis transmembrane conductance regulator chloride channel |
| 01/24/2002 | WO2002005786A1 Pharmaceutical composition improved in peroral absorbability |
| 01/24/2002 | WO2001058875A3 Substituted 1,2,3,4- tetrahydroquinoline-2-carboxylic acid derivatives |
| 01/24/2002 | WO2001054706A3 Method for treating kidney disorders |
| 01/24/2002 | WO2001046258A3 Transporters and ion channels |
| 01/24/2002 | WO2001038305A3 Novel il-8 receptor antagonists |
| 01/24/2002 | WO2001034768A3 15 human secreted proteins |
| 01/24/2002 | WO2001027107A3 Heterocyclic sodium/proton exchange inhibitors and method |
| 01/24/2002 | WO2001019860A3 Proteins associated with cell differentiation |
| 01/24/2002 | WO2001012819A3 Protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 01/24/2002 | WO2001000655A3 Therapeutic peptides derived from subsequences of bpi |
| 01/24/2002 | WO2000071107A8 New pharmaceutical combinations for nos inhibitors |
| 01/24/2002 | US20020010949 Cloning using donor nuclei from differentiated fetal and adult cells |
| 01/24/2002 | US20020010351 Anticancer agents |
| 01/24/2002 | US20020010316 Thiazole derivatives |
| 01/24/2002 | US20020010315 Treatment or amelioration of symptoms of adult respiratory distress syndrome, septic shock, and multiple organ failure. |
| 01/24/2002 | US20020010216 Mixture of norepinephrine reuptake inhibitors and antimuscarinic agents; treating disorders or diseases of the central nervous system, and particularly useful in treating incontinence. |
| 01/24/2002 | US20020010184 Inhibitors of prenyl-protein transferase |
| 01/24/2002 | US20020010174 1,4-diazepine-2-one derivatives as neurokinin antagonist |
| 01/24/2002 | US20020010170 Pyrimido(1,6-b)pyridazine derivatives used as p38 inhibitors a mammalian protein kinase is involved in cell proliferation, cell death and response to extracellular stimuli |
| 01/24/2002 | US20020010168 Boswellic acid, salt or derivatives for preventing and/or combatting diseases caused by increased leucocytic elastase or plasmin activity in human or veterinary medincine, usedfor pulmonary emphysema, acute respiratory distress etc. |
| 01/24/2002 | US20020010158 Derivatives of 5-pyridylalkylphosphonates and 5-pyridylalkylmalonates useful drugs for treatment of cardiovascular related diseases and diabetes mellitus related diseases |
| 01/24/2002 | US20020010146 Nitrosated and nitrosylated taxanes, compositions and methods of use |
| 01/24/2002 | US20020009776 Fibroblast growth factor receptor-like molecules and uses thereof |
| 01/24/2002 | DE10033459A1 New aminomethyl-substituted bicyclic compounds, useful for treating urinary incontinence, pruritis, tinnitus, diarrhea or especially pain |
| 01/24/2002 | CA2697031A1 Detection and treatment of polycystic kidney disease |
| 01/24/2002 | CA2416245A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| 01/24/2002 | CA2415896A1 Use of fluorescein derivatives for the treatment of diseases responsive to the activation of the cystic fibrosis transmembrane conductance regulator chloride channel |
| 01/24/2002 | CA2415701A1 Compositions and methods for the treatment of skin damage |
| 01/24/2002 | CA2415673A1 Tetrazole derivatives |
| 01/24/2002 | CA2415665A1 Pyrrolidine-2-carboxylic acid hydrazide derivatives for use as metalloprotease inhibitors |
| 01/24/2002 | CA2415557A1 Compounds for the treatment of sexual dysfunction |
| 01/24/2002 | CA2415392A1 Pharmaceutical combinations for treatment and prevention of diabetes mellitus |
| 01/23/2002 | EP1174431A2 2-Phenyl-substituited Imidazotriazinones as Phoshodiesterase Inhibitors |
| 01/23/2002 | EP1174143A1 Green tea extract and use thereof in treating renal dysfunction induced by cyclosporins or ascomycins |
| 01/23/2002 | EP1173767A1 Peptide epitopes recognized by disease promoting cd4+ t lymphocytes |
| 01/23/2002 | EP1173757A1 Diagnosis of human kidney diseases |
| 01/23/2002 | EP1173566A2 Human membrane-associated proteins |
| 01/23/2002 | EP1173477A1 49 human secreted proteins |
| 01/23/2002 | EP1173468A1 Integrin receptor antagonists |
| 01/23/2002 | EP1173462A1 50 human secreted proteins |
| 01/23/2002 | EP1173443A1 Cyclic urea and cyclic amide derivatives |
| 01/23/2002 | EP1173440A1 Tetracyclic azepinoindole compounds as 5-ht receptor ligands |
| 01/23/2002 | EP1173434A2 Thiazolidinedione derivative and its use as antidiabetic |
| 01/23/2002 | EP1173433A1 Cyanopyrroles as progesterone receptor agonists |
| 01/23/2002 | EP1173423A1 Benzimidazolones and analogues and their use as progesterone receptor ligands |
| 01/23/2002 | EP1173201A1 Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit |
| 01/23/2002 | EP0854711B1 gamma-RAR ANTAGONIST LIGAND OR alpha-RAR AGONIST LIGAND AS AN APOPTOSIS INHIBITOR |
| 01/23/2002 | CN1332801A Connective tissue growth factor (CTGF) and methods of use |
| 01/23/2002 | CN1332731A Substituted benzimidazoles and their prep. and use |
| 01/23/2002 | CN1332711A Vitamin D analogues |
| 01/23/2002 | CN1332635A Controlled release formulation comprising GnRH-II |
| 01/23/2002 | CN1332167A Eprosartan dihydrate and its prep. |
| 01/22/2002 | US6340742 Erythropoietin conjugates |
| 01/22/2002 | US6340685 Antiinflammatory agents |
| 01/22/2002 | US6340681 Useful as analgesics in mammals |
| 01/22/2002 | US6340679 Guanidine derivatives as inhibitors of cell adhesion |
| 01/22/2002 | US6340668 Administering bone morphogenetic protein-11 (bmp-11) to neuronal cells effective to promote the survival of cells |
| 01/22/2002 | CA2259962C Therapeutic applications of t-bam (cd40l) technology to treat diseases involving smooth muscle cells |
| 01/22/2002 | CA2093794C 1'-aminospiro¬isoquinoline-4(1h),3-pyrrolidine|-1,2',3,5'-(2h)-tetrones and analogs thereof useful as aldose reductase inhibitors |
| 01/22/2002 | CA2051460C Pharmaceutical compounds |
| 01/17/2002 | WO2002004953A2 Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers |
| 01/17/2002 | WO2002004612A2 Drug metabolizing enzymes |
| 01/17/2002 | WO2002004509A2 Gene expression, genome alteration and reporter expression in myofibroblasts and myofibroblast-like cells |
| 01/17/2002 | WO2002004496A2 Fimh adhesin proteins and methods of use |
| 01/17/2002 | WO2002004487A2 Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses |
| 01/17/2002 | WO2002004474A1 Adenosine compound and pharmaceutical composition containing the same |
| 01/17/2002 | WO2002004434A1 Colchinol derivatives as vascular damaging agents |
| 01/17/2002 | WO2002004429A1 Pyrimidine derivatives |
| 01/17/2002 | WO2002003989A2 Use of substituted indole compounds for treating sphincter incontinence |
| 01/17/2002 | WO2002003980A1 Anti-inflammatory and analgesic agents |
| 01/17/2002 | WO2002003912A2 Novel c-4 substituted retinoids |
| 01/17/2002 | WO2001064200A3 Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy |
| 01/17/2002 | WO2001049838A3 Cis-acting regulatory nucleic acid sequences in the parathyroid hormone 3'-untranslated region |
| 01/17/2002 | WO2001044291A3 Polynucleotid encoding the rg1 polypeptide |
| 01/17/2002 | WO2001022972A3 Immunostimulatory nucleic acids |
| 01/17/2002 | WO2001021259A3 Use and compositions for treating platelet-related disorders using anagrelide |
| 01/17/2002 | WO2001019407A3 Taxane prodrugs |
| 01/17/2002 | WO2001012598A3 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |